Mother-to-child Hepatitis D Transmission

Status Completed

Clinical Trial Summary

HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication. Nucleosides analogues have only a minor impact on quantitative HBs Ag level. Data about vertical HDV transmission are old, justifying a new study.

Clinical Trial Description

Hepatitis B Virus (HBV) can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA viral load during the last trimester of pregnancy. Nucleosides analogues, lamivudine, telbivudine, or nucleotides analogues, tenofovir DF decrease HBV mother-to-child transmission risk, and are recommended in Guidelines (EASL 2012) for pregnant women with HBV DNA above 1,000 000 I.U/mL. HDV is a defective virus using HBs Ag for its own replication. HDV-HBV co-infection is a re-emerging infectious disease in western countries, due to immigration of people coming from endemic areas. Nucleosides analogues have only a minor impact on quantitative HBs Ag level (Boyd A et al. AIDS Research and Human Retroviruses 2013). Data about vertical HDV transmission are old (Rizzetto, et al. J Med Virol 1982), before a large use of nucleosides/nucleotides analogues in HBV infected pregnant women, justifying a new study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02044055
Study type	Observational
Source	Hopital Lariboisière
Contact
Status	Completed
Phase	N/A
Start date	October 2014
Completion date	April 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02375906` - The Hepatitis Delta International Network
Not yet recruiting	`NCT05394623` - Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
Recruiting	`NCT04863703` - Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Not yet recruiting	`NCT06397859` - Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Recruiting	`NCT00001971` - Evaluation of Patients With Liver Disease
Recruiting	`NCT05928000` - HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
Recruiting	`NCT06122285` - Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Terminated	`NCT04847440` - A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection	Phase 2
Not yet recruiting	`NCT06264583` - HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
Recruiting	`NCT05936073` - DELTA DESCRIBE: the French Collaborative Project
Completed	`NCT00932971` - HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis	Phase 2
Completed	`NCT06360484` - Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Completed	`NCT02511431` - Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir	Phase 2
Not yet recruiting	`NCT05451082` - Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
Recruiting	`NCT05903742` - Standardising Care for Hepatitis Delta in the Netherlands
Not yet recruiting	`NCT03362866` - Epidemiology of Hepatitis B, C and Delta in Reunion Island
Terminated	`NCT01316185` - Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)	Phase 1
Recruiting	`NCT05264272` - Disease Loads and Status of Treatment
Completed	`NCT05002907` - Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
Not yet recruiting	`NCT05467553` - A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection	Phase 2